v3.26.1
Consolidated Statements of Changes in Equity - USD ($)
shares in Millions, $ in Millions
Total
Ordinary Shares [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Treasury Shares [Member]
Total Teva shareholders' equity [Member]
Non-controlling Interests [Member]
Beginning balance at Dec. 31, 2024 $ 5,380 $ 58 $ 27,764 $ (15,173) $ (3,148) $ (4,128) $ 5,373 $ 7
Beginning balance, shares at Dec. 31, 2024   1,240            
Net income (loss) 497     497        
Net income (loss) 497           497  
Other comprehensive income (loss) 717       717 [1]   717  
Issuance of Shares, shares   13            
Stock-based compensation expense 72   72       72  
Proceeds from exercise of options 3   3       3  
Purchase of shares from non-controlling interests [2] 165   165       165  
Ending balance at Jun. 30, 2025 6,834 $ 58 28,003 (14,676) (2,431) (4,128) 6,827 7
Ending balance, shares at Jun. 30, 2025   1,253            
Beginning balance at Mar. 31, 2025 6,269 $ 58 27,965 (14,958) (2,675) (4,128) 6,262 7
Beginning balance, shares at Mar. 31, 2025   1,253            
Net income (loss) 283     282        
Net income (loss) 282           282  
Other comprehensive income (loss) 244       244   244  
Stock-based compensation expense 38   38       38  
Ending balance at Jun. 30, 2025 6,834 $ 58 28,003 (14,676) (2,431) (4,128) 6,827 7
Ending balance, shares at Jun. 30, 2025   1,253            
Beginning balance at Dec. 31, 2025 7,914 $ 58 28,133 (13,762) (2,391) (4,128) 7,910 4
Beginning balance, shares at Dec. 31, 2025   1,256            
Net income (loss) (206)     (207)        
Net income (loss) (207)           (207)  
Other comprehensive income (loss) (74)       (74)   (74)  
Issuance of Shares, shares   15            
Stock-based compensation expense 83   83       83  
Proceeds from exercise of options 39   39       39  
Ending balance at Jun. 30, 2026 7,757 $ 59 28,256 (13,969) (2,465) (4,128) 7,753 4
Ending balance, shares at Jun. 30, 2026   1,271            
Beginning balance at Mar. 31, 2026 8,232 $ 59 28,203 (13,394) (2,512) (4,128) 8,228 4
Beginning balance, shares at Mar. 31, 2026   1,271            
Net income (loss) (575)     (576)        
Net income (loss) (576)           (576)  
Other comprehensive income (loss) 47       47   47  
Stock-based compensation expense 40   40       40  
Proceeds from exercise of options 13   13       13  
Ending balance at Jun. 30, 2026 $ 7,757 $ 59 $ 28,256 $ (13,969) $ (2,465) $ (4,128) $ 7,753 $ 4
Ending balance, shares at Jun. 30, 2026   1,271            
[1] Amounts do not include a $27 million gain from foreign currency translation adjustments attributable to redeemable and non-redeemable non-controlling interests.
[2] In connection with the sale of Teva’s business venture in Japan.